GlassScriptPhysician profile
Carl K Atallah
NPI 1922269190
$10,573.05
in general payments reported to CMS, 2019-2025
40 companies · $2,128 in 2025
The $2,128 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,142 · 2020: $1,191 · 2021: $1,395 · 2022: $1,190 · 2023: $1,865 · 2024: $1,662 · 2025: $2,128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,555 · Education: $98.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,555.26 |
| Education | $98.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,045.65 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,244.77 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Janssen Biotech, INC. | $1,081.11 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $898.44 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $511.38 | 2019-2025 | |
| Pfizer INC. | $508.82 | 2019-2025 | |
| Qol Medical, LLC | $461.68 | 2023-2025 | Sucraid, Sucraid |
| Medtronic, INC. | $311.38 | 2023-2025 | Gi Genius, Sonicision |
| Celgene Corporation | $270.96 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $242.28 | 2021-2022 | |
| Gi Supply, INC. | $240.39 | 2020 | |
| Ardelyx, INC. | $222.33 | 2023-2025 | Ibsrela |
| Allergan, INC. | $222.17 | 2019-2020 | |
| Genzyme Corporation | $215.13 | 2023-2025 | |
| Boston Scientific Corporation | $181.95 | 2019-2023 | Orcapod |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $181.83 | 2019-2023 | Suflave, Sutab |
| Madrigal Pharmaceuticals | $181.48 | 2024-2025 | Rezdiffra, Resmetirom |
| Covidien LP | $173.07 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $158.23 | 2020-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $128.01 | 2020-2024 | Dificid |
| Redhill Biopharma INC. | $109.44 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $107.11 | 2023-2025 | Dupixent |
| Merit Medical Systems INC | $102.92 | 2025 | Endomaxx Stent and Delivery System, Esophyx |
| Vivus LLC | $95.24 | 2019-2024 | Qsymia |
| Lilly USA, LLC | $84.25 | 2024-2025 | Omvoh |
| W. L. Gore & Associates, INC. | $84.14 | 2025 | Gore Seamguard Bioabsorbable Staple Line Reinforce |
| Cook Medical LLC | $79.32 | 2019-2023 | Hemospray |
| Aimmune Therapeutics, INC. | $62.97 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $56.35 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $46.52 | 2023 | |
| Phathom Pharmaceuticals, INC. | $41.22 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.31 | 2024 | Cyltezo |
| Ucb, INC. | $36.96 | 2019 | |
| Ferring Pharmaceuticals INC. | $28.36 | 2020-2021 | |
| Amgen INC. | $24.88 | 2021 | |
| Amag Pharmaceuticals, INC. | $21.95 | 2021 | |
| Daiichi Sankyo INC. | $21.82 | 2021 | |
| Endogastric Solutions, INC | $19.23 | 2023 | Esophyx |
| Exact Sciences Corporation | $14.78 | 2023 | Cologuard Collection Kit |
| Echosens North America, INC. | $14.22 | 2024 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Atallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.